William Blair analyst Raju Prasad maintained a Buy rating on Krystal Biotech (KRYS) today. The company’s shares closed last Monday at $51.56, close to its 52-week high of $53.14.
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 12.9% and a 52.6% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Rocket Pharmaceuticals.
Currently, the analyst consensus on Krystal Biotech is a Strong Buy with an average price target of $72.50, representing a 41.9% upside. In a report issued on November 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $59.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $53.14 and a one-year low of $16.82. Currently, Krystal Biotech has an average volume of 159.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.
